⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

June 7, 2024BMC OphthalmologyOpen Access

Predictive factors and adalimumab efficacy in managing chronic recurrence Vogt-Koyanagi-Harada disease

Hui Feng Weixin Chen Jianzhu Yang Haorong Kong Hongyu Li Yuan He Hong Wang

View Full Paper

Ask AI

Bookmark

Share

Abstract

This study explores prognostic factors influencing Vogt-Koyanagi-Harada (VKH) disease and observes the efficacy and safety of Adalimumab (ADA) in treating recurrence in Vogt-Koyanagi-Harada (VKH) patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Feng et al. (2024) studied this question.

synapsesocial.com/papers/68e65ab4b6db6435875e9212 https://doi.org/10.1186/s12886-024-03511-9

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Clinical and Transcriptional Profiles Reveal the Treatment Effect of Adalimumab in Patients with Initial-Onset and Recurrent Vogt–Koyanagi–Harada Disease2024 · 1 citations
2Efficacy of Tumor Necrosis Factor-α Inhibitor Adalimumab in Chronic Recurrent Vogt–Koyanagi–Harada Disease2025 · 1 citations
3Cost-Effectiveness Analysis of Adalimumab Versus Cyclosporine for Vogt-Koyanagi-Harada Disease: A Randomized Controlled Study2024
4Spectrum of Manifestations and Therapeutic Outcomes in Vogt–Koyanagi–Harada Syndrome2025
5Retrospective analysis of Vogt-Koyanagi-Harada’s recurrence within a case series of nineteen patients followed between 2003 and 2018 in an academic center2024